English
Segment disclosures
Company overviewLIGAND PHARMACEUTICALS INC
Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.
Revenue · Reported segment facts
Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.
Operating Segments · Contract Revenue · Ligand Core Business Segment
Consolidation Items · Product Or Service · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=lgnd:ContractRevenueMember;us-gaap:StatementBusinessSegmentsAxis=lgnd:LigandCoreBusinessSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-04-01 – 2022-06-30 | 2762000 | USD | 20220809 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 13723000 | USD | 20220809 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 7729000 | USD | 20220809 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 15936000 | USD | 20220809 | Open filing evidence |
Operating Segments · Ligand Core Business Segment
Consolidation Items · Statement Business Segments
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=lgnd:LigandCoreBusinessSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-07-01 – 2022-09-30 | 59221000 | USD | 20221108 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 145863000 | USD | 20221108 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 50127000 | USD | 20220809 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 86642000 | USD | 20220809 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 59695000 | USD | 20221108 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 185140000 | USD | 20221108 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 78854000 | USD | 20220809 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 125445000 | USD | 20220809 | Open filing evidence |
Operating Segments · Ligand Core Business Segment · Royalty
Consolidation Items · Statement Business Segments · Product Or Service
Source dimensions
srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=lgnd:LigandCoreBusinessSegmentMember;srt:ProductOrServiceAxis=us-gaap:RoyaltyMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-04-01 – 2022-06-30 | 17820000 | USD | 20220809 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 31252000 | USD | 20220809 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 8616000 | USD | 20220809 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 15728000 | USD | 20220809 | Open filing evidence |
Contract Revenue · Operating Segments · Ligand Core Business Segment
Product Or Service · Consolidation Items · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=lgnd:ContractRevenueMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=lgnd:LigandCoreBusinessSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-07-01 – 2022-09-30 | 4017000 | USD | 20221108 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 17740000 | USD | 20221108 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 8954000 | USD | 20221108 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 24889000 | USD | 20221108 | Open filing evidence |
Contract Revenue · Ligand Core Business Segment · Operating Segments
Product Or Service · Statement Business Segments · Consolidation Items
Source dimensions
srt:ProductOrServiceAxis=lgnd:ContractRevenueMember;us-gaap:StatementBusinessSegmentsAxis=lgnd:LigandCoreBusinessSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-01-01 – 2022-03-31 | 10961000 | USD | 20220509 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 8207000 | USD | 20220509 | Open filing evidence |
Contract Revenue · Omni Ab Technologies Segment · Operating Segments
Product Or Service · Statement Business Segments · Consolidation Items
Source dimensions
srt:ProductOrServiceAxis=lgnd:ContractRevenueMember;us-gaap:StatementBusinessSegmentsAxis=lgnd:OmniAbTechnologiesSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-01-01 – 2022-03-31 | 8915000 | USD | 20220509 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 8559000 | USD | 20220509 | Open filing evidence |
Material Sales Captisol Core · Ligand Core Business Segment · Operating Segments
Product Or Service · Statement Business Segments · Consolidation Items
Source dimensions
srt:ProductOrServiceAxis=lgnd:MaterialSalesCaptisolCoreMember;us-gaap:StatementBusinessSegmentsAxis=lgnd:LigandCoreBusinessSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-01-01 – 2022-03-31 | 6226000 | USD | 20220509 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 1253000 | USD | 20220509 | Open filing evidence |
Royalty · Operating Segments · Ligand Core Business Segment
Product Or Service · Consolidation Items · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=us-gaap:RoyaltyMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=lgnd:LigandCoreBusinessSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-07-01 – 2022-09-30 | 19255000 | USD | 20221108 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 50507000 | USD | 20221108 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 15648000 | USD | 20221108 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 31376000 | USD | 20221108 | Open filing evidence |
Operating Segments · Cydex Pharmaceuticals Inc
Consolidation Items · Statement Business Segments
Source dimensions
us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=lgnd:CydexPharmaceuticalsIncMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2015-07-01 – 2015-09-30 | 8816000 | USD | 20151109 | Open filing evidence |
| 2015-01-01 – 2015-09-30 | 27630000 | USD | 20151109 | Open filing evidence |
| 2015-04-01 – 2015-06-30 | 13218000 | USD | 20150805 | Open filing evidence |
| 2015-01-01 – 2015-06-30 | 18814000 | USD | 20150805 | Open filing evidence |
| 2014-07-01 – 2014-09-30 | 8549000 | USD | 20151109 | Open filing evidence |
| 2014-01-01 – 2014-09-30 | 22632000 | USD | 20151109 | Open filing evidence |
| 2014-04-01 – 2014-06-30 | 4916000 | USD | 20150805 | Open filing evidence |
| 2014-01-01 – 2014-06-30 | 14083000 | USD | 20150805 | Open filing evidence |
Operating Segments · Ligand
Consolidation Items · Statement Business Segments
Source dimensions
us-gaap:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=lgnd:LigandMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2015-07-01 – 2015-09-30 | 8885000 | USD | 20151109 | Open filing evidence |
| 2015-01-01 – 2015-09-30 | 23092000 | USD | 20151109 | Open filing evidence |
| 2015-04-01 – 2015-06-30 | 5200000 | USD | 20150805 | Open filing evidence |
| 2015-01-01 – 2015-06-30 | 14206000 | USD | 20150805 | Open filing evidence |
| 2014-07-01 – 2014-09-30 | 6424000 | USD | 20151109 | Open filing evidence |
| 2014-01-01 – 2014-09-30 | 18907000 | USD | 20151109 | Open filing evidence |
| 2014-04-01 – 2014-06-30 | 5692000 | USD | 20150805 | Open filing evidence |
| 2014-01-01 – 2014-06-30 | 12483000 | USD | 20150805 | Open filing evidence |
Cydex
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lgnd:CydexMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2012-07-01 – 2012-09-30 | 2667000 | USD | 20121114 | Open filing evidence |
| 2012-01-01 – 2012-09-30 | 6025000 | USD | 20121114 | Open filing evidence |
| 2012-04-01 – 2012-06-30 | 1813000 | USD | 20121114 | Open filing evidence |
| 2012-01-01 – 2012-06-30 | 3348000 | USD | 20121114 | Open filing evidence |
| 2011-07-01 – 2011-09-30 | 2450000 | USD | 20121114 | Open filing evidence |
| 2011-01-01 – 2011-09-30 | 8383000 | USD | 20121114 | Open filing evidence |
Cydex Pharmaceuticals Inc
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lgnd:CydexPharmaceuticalsIncMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2015-01-01 – 2015-03-31 | 5596000 | USD | 20150511 | Open filing evidence |
| 2014-01-01 – 2014-12-31 | 37364000 Restated | USD | 20150223 | Open filing evidence |
| 2014-07-01 – 2014-09-30 | 8549000 | USD | 20141031 | Open filing evidence |
| 2014-01-01 – 2014-09-30 | 22632000 | USD | 20141031 | Open filing evidence |
| 2014-04-01 – 2014-06-30 | 4916000 | USD | 20140805 | Open filing evidence |
| 2014-01-01 – 2014-06-30 | 14083000 | USD | 20140805 | Open filing evidence |
| 2014-01-01 – 2014-03-31 | 9167000 | USD | 20150511 | Open filing evidence |
| 2013-01-01 – 2013-12-31 | 27537000 | USD | 20150223 | Open filing evidence |
| 2013-07-01 – 2013-09-30 | 8274000 | USD | 20141031 | Open filing evidence |
| 2013-01-01 – 2013-09-30 | 19448000 | USD | 20141031 | Open filing evidence |
| 2013-04-01 – 2013-06-30 | 5760000 | USD | 20140805 | Open filing evidence |
| 2013-01-01 – 2013-06-30 | 11174000 | USD | 20140805 | Open filing evidence |
| 2013-01-01 – 2013-03-31 | 5414000 | USD | 20140507 | Open filing evidence |
| 2012-01-01 – 2012-12-31 | 11806000 | USD | 20150223 | Open filing evidence |
| 2012-07-01 – 2012-09-30 | 2667000 | USD | 20131108 | Open filing evidence |
| 2012-01-01 – 2012-09-30 | 6025000 | USD | 20131108 | Open filing evidence |
| 2012-04-01 – 2012-06-30 | 1813000 | USD | 20130801 | Open filing evidence |
| 2012-01-01 – 2012-06-30 | 3348000 | USD | 20130801 | Open filing evidence |
| 2012-01-01 – 2012-03-31 | 1535000 | USD | 20130508 | Open filing evidence |
| 2011-01-01 – 2011-12-31 | 16247000 | USD | 20130314 | Open filing evidence |
Development And Licensing Of Biopharmaceutical Assets
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lgnd:DevelopmentAndLicensingOfBiopharmaceuticalAssetsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-07-01 – 2026-09-30 | 78746000 | USD | 20261030 | Open filing evidence |
| 2026-01-01 – 2026-09-30 | 194161000 | USD | 20261030 | Open filing evidence |
| 2026-04-01 – 2026-06-30 | 63693000 | USD | 20260807 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 115415000 | USD | 20260807 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 51722000 | USD | 20260508 | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 268087000 | USD | 20260227 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 115461000 | USD | 20261030 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 208421000 | USD | 20261030 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 47627000 | USD | 20260807 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 92960000 | USD | 20260807 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 45333000 | USD | 20260508 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 167133000 | USD | 20260227 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 51812000 | USD | 20251107 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 124321000 | USD | 20251107 | Open filing evidence |
| 2024-04-01 – 2024-06-30 | 41531000 | USD | 20250808 | Open filing evidence |
| 2024-01-01 – 2024-06-30 | 72509000 | USD | 20250808 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 30978000 | USD | 20250509 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 131314000 | USD | 20260227 | Open filing evidence |
| 2022-01-01 – 2022-12-31 | 196245000 | USD | 20250228 | Open filing evidence |
Ligand Core Business Segment · Operating Segments
Statement Business Segments · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lgnd:LigandCoreBusinessSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-01-01 – 2022-03-31 | 36515000 | USD | 20220509 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 46591000 | USD | 20220509 | Open filing evidence |
Ligand Core Business Segment · Material Sales Captisol COVID · Operating Segments
Statement Business Segments · Product Or Service · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lgnd:LigandCoreBusinessSegmentMember;srt:ProductOrServiceAxis=lgnd:MaterialSalesCaptisolCOVIDMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-01-01 – 2022-03-31 | 5896000 | USD | 20220509 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 30019000 | USD | 20220509 | Open filing evidence |
Ligand Core Business Segment · Royalty · Operating Segments
Statement Business Segments · Product Or Service · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lgnd:LigandCoreBusinessSegmentMember;srt:ProductOrServiceAxis=us-gaap:RoyaltyMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-01-01 – 2022-03-31 | 13432000 | USD | 20220509 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 7112000 | USD | 20220509 | Open filing evidence |
Ligand
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lgnd:LigandMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2015-01-01 – 2015-03-31 | 9006000 | USD | 20150511 | Open filing evidence |
| 2014-01-01 – 2014-12-31 | 27174000 Restated | USD | 20150223 | Open filing evidence |
| 2014-07-01 – 2014-09-30 | 6424000 | USD | 20141031 | Open filing evidence |
| 2014-01-01 – 2014-09-30 | 18907000 | USD | 20141031 | Open filing evidence |
| 2014-04-01 – 2014-06-30 | 5692000 | USD | 20140805 | Open filing evidence |
| 2014-01-01 – 2014-06-30 | 12483000 | USD | 20140805 | Open filing evidence |
| 2014-01-01 – 2014-03-31 | 6791000 | USD | 20150511 | Open filing evidence |
| 2013-01-01 – 2013-12-31 | 21436000 | USD | 20150223 | Open filing evidence |
| 2013-07-01 – 2013-09-30 | 4731000 | USD | 20141031 | Open filing evidence |
| 2013-01-01 – 2013-09-30 | 14789000 | USD | 20141031 | Open filing evidence |
| 2013-04-01 – 2013-06-30 | 3820000 | USD | 20140805 | Open filing evidence |
| 2013-01-01 – 2013-06-30 | 10057000 | USD | 20140805 | Open filing evidence |
| 2013-01-01 – 2013-03-31 | 6237000 | USD | 20140507 | Open filing evidence |
| 2012-01-01 – 2012-12-31 | 19582000 | USD | 20150223 | Open filing evidence |
| 2012-07-01 – 2012-09-30 | 3708000 | USD | 20131108 | Open filing evidence |
| 2012-01-01 – 2012-09-30 | 11728000 | USD | 20131108 | Open filing evidence |
| 2012-04-01 – 2012-06-30 | 3929000 | USD | 20130801 | Open filing evidence |
| 2012-01-01 – 2012-06-30 | 8030000 | USD | 20130801 | Open filing evidence |
| 2012-01-01 – 2012-03-31 | 4101000 | USD | 20130508 | Open filing evidence |
| 2011-01-01 – 2011-12-31 | 13790000 | USD | 20130314 | Open filing evidence |
| 2011-07-01 – 2011-09-30 | 3291000 | USD | 20121114 | Open filing evidence |
| 2011-01-01 – 2011-09-30 | 8718000 | USD | 20121114 | Open filing evidence |
Omni Ab Technologies Segment · Operating Segments
Statement Business Segments · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lgnd:OmniAbTechnologiesSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-07-01 – 2022-09-30 | 6867000 | USD | 20221108 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 23337000 | USD | 20221108 | Open filing evidence |
| 2022-04-01 – 2022-06-30 | 7292000 | USD | 20220809 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 16470000 | USD | 20220809 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 9178000 | USD | 20220509 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 5140000 | USD | 20221108 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 19520000 | USD | 20221108 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 5821000 | USD | 20220809 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 14380000 | USD | 20220809 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 8559000 | USD | 20220509 | Open filing evidence |
Omni Ab Technologies Segment · Operating Segments · Contract Revenue
Statement Business Segments · Consolidation Items · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lgnd:OmniAbTechnologiesSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=lgnd:ContractRevenueMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-04-01 – 2022-06-30 | 7153000 | USD | 20220809 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 16068000 | USD | 20220809 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 5821000 | USD | 20220809 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 14380000 | USD | 20220809 | Open filing evidence |
Omni Ab Technologies Segment · Operating Segments · Royalty
Statement Business Segments · Consolidation Items · Product Or Service
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lgnd:OmniAbTechnologiesSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;srt:ProductOrServiceAxis=us-gaap:RoyaltyMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-04-01 – 2022-06-30 | 139000 | USD | 20220809 | Open filing evidence |
| 2022-01-01 – 2022-06-30 | 402000 | USD | 20220809 | Open filing evidence |
| 2021-04-01 – 2021-06-30 | 0 | USD | 20220809 | Open filing evidence |
| 2021-01-01 – 2021-06-30 | 0 | USD | 20220809 | Open filing evidence |
Omni Ab Technologies Segment · Contract Revenue · Operating Segments
Statement Business Segments · Product Or Service · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lgnd:OmniAbTechnologiesSegmentMember;srt:ProductOrServiceAxis=lgnd:ContractRevenueMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-07-01 – 2022-09-30 | 6285000 | USD | 20221108 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 22353000 | USD | 20221108 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 5140000 | USD | 20221108 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 19520000 | USD | 20221108 | Open filing evidence |
Omni Ab Technologies Segment · Royalty · Operating Segments
Statement Business Segments · Product Or Service · Consolidation Items
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=lgnd:OmniAbTechnologiesSegmentMember;srt:ProductOrServiceAxis=us-gaap:RoyaltyMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2022-07-01 – 2022-09-30 | 582000 | USD | 20221108 | Open filing evidence |
| 2022-01-01 – 2022-09-30 | 984000 | USD | 20221108 | Open filing evidence |
| 2022-01-01 – 2022-03-31 | 263000 | USD | 20220509 | Open filing evidence |
| 2021-07-01 – 2021-09-30 | 0 | USD | 20221108 | Open filing evidence |
| 2021-01-01 – 2021-09-30 | 0 | USD | 20221108 | Open filing evidence |
| 2021-01-01 – 2021-03-31 | 0 | USD | 20220509 | Open filing evidence |